Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ETV4 |
| Gene Name: | ETV4 |
| Protein Full Name: | ETS translocation variant 4 |
| Alias: | Adenovirus E1A enhancer-binding protein; E1AF; E1A-F |
| Mass (Da): | 53938 |
| Number AA: | 484 |
| UniProt ID: | P43268 |
| Locus ID: | 2118 |
| COSMIC ID: | ETV4 |
| Gene location on chromosome: | 17q21; 17q21.31 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19535 |
| Percent of cancer specimens with mutations: | 0.34 |
| Deregulated in translocations: | Prostate Cancer. Fusion partner TMPRSS2. Other fusion parners DDX5, EWSR1, CANT1 and KLK2 |
| Normal role description: | ETV4 is a nuclear localized ETS family transcription factor which recognizes Ets-binding domains on target genes. It was originally identified as a transcription factor able to bind enhancer elements of the adenovirus E1A gene. Within the cell ETV4 regulates various processes including neuronal pathfinding, mammary gland development and male sexual function. Overexpression of ETV4 has been observed in breast, gastric, lung, skin, prostate and colorectal cancers. ETV4's role in cancer progression is in regulating the expression of Ets-mediated oncogenes such as cyclooxygenase-2, matrix metalloproteinases, hepatocyte growth factor and epiderminal growth facot receptor. The ETV4 appears to be relatively mobile and translocation events with various fusion partners have been implicated in cancer development. ETV4 is classified as an oncogene. |